[go: up one dir, main page]

UA91051C2 - Лекарственная форма тиенопиридинового ингибитора агрегации тромбоцитов - Google Patents

Лекарственная форма тиенопиридинового ингибитора агрегации тромбоцитов

Info

Publication number
UA91051C2
UA91051C2 UAA200712993A UAA200712993A UA91051C2 UA 91051 C2 UA91051 C2 UA 91051C2 UA A200712993 A UAA200712993 A UA A200712993A UA A200712993 A UAA200712993 A UA A200712993A UA 91051 C2 UA91051 C2 UA 91051C2
Authority
UA
Ukraine
Prior art keywords
formulation
platelet aggregation
aggregation inhibitor
thienopyridine
thienopyridine platelet
Prior art date
Application number
UAA200712993A
Other languages
English (en)
Ukrainian (uk)
Inventor
Девид Брайан Дзенник
Тамара Бэт Эдельман
Питер Ллойд Орен
Роберт Луис Терник
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37198935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA91051(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of UA91051C2 publication Critical patent/UA91051C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
UAA200712993A 2005-06-10 2006-06-06 Лекарственная форма тиенопиридинового ингибитора агрегации тромбоцитов UA91051C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68918305P 2005-06-10 2005-06-10

Publications (1)

Publication Number Publication Date
UA91051C2 true UA91051C2 (ru) 2010-06-25

Family

ID=37198935

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200712993A UA91051C2 (ru) 2005-06-10 2006-06-06 Лекарственная форма тиенопиридинового ингибитора агрегации тромбоцитов

Country Status (34)

Country Link
US (1) US20080176893A1 (ru)
EP (1) EP1896019B1 (ru)
JP (1) JP2008543755A (ru)
KR (2) KR20080008413A (ru)
CN (1) CN101193633B (ru)
AR (1) AR054283A1 (ru)
AT (1) ATE441413T1 (ru)
AU (1) AU2006258102B2 (ru)
BR (1) BRPI0611350B8 (ru)
CA (1) CA2611668C (ru)
CY (1) CY1109502T1 (ru)
DE (1) DE602006008942D1 (ru)
DK (1) DK1896019T3 (ru)
DO (1) DOP2006000126A (ru)
EA (1) EA011693B1 (ru)
EC (1) ECSP077984A (ru)
ES (1) ES2330373T3 (ru)
HR (1) HRP20090516T1 (ru)
IL (1) IL187830A0 (ru)
MA (1) MA29688B1 (ru)
MX (1) MX2007015431A (ru)
MY (1) MY151038A (ru)
NO (1) NO20076317L (ru)
NZ (1) NZ564003A (ru)
PE (1) PE20070320A1 (ru)
PL (1) PL1896019T3 (ru)
PT (1) PT1896019E (ru)
RS (1) RS51194B (ru)
SI (1) SI1896019T1 (ru)
TN (1) TNSN07466A1 (ru)
TW (1) TWI318571B (ru)
UA (1) UA91051C2 (ru)
WO (1) WO2006135605A2 (ru)
ZA (1) ZA200710697B (ru)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2100606A4 (en) * 2006-12-07 2009-12-30 Daiichi Sankyo Co Ltd PREPARATION WITH FILM COVER AND IMPROVED STABILITY
AU2007333302A1 (en) * 2006-12-07 2008-06-19 Eli Lilly And Company An article comprising prasugrel
WO2008072533A1 (ja) * 2006-12-07 2008-06-19 Daiichi Sankyo Company, Limited 固形製剤の製造方法
CN101600431B (zh) * 2006-12-07 2011-09-07 第一三共株式会社 具有改进贮存稳定性的药物组合物
KR101442862B1 (ko) * 2006-12-07 2014-09-22 다이이찌 산쿄 가부시키가이샤 만니톨 또는 유당을 함유하는 고형 제제
TWI482641B (zh) * 2006-12-07 2015-05-01 Daiichi Sankyo Co Ltd 含有低取代度羥丙基纖維素之醫藥組成物
KR101505212B1 (ko) * 2007-03-02 2015-03-23 다이이찌 산쿄 가부시키가이샤 고순도 프라수그렐염산염의 제조 방법
EP2152078B8 (en) 2007-04-27 2021-03-17 CyDex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
GB2450117A (en) * 2007-06-13 2008-12-17 Reckitt Benckiser Healthcare A water- and oxygen-occlusive blister tablet pack
WO2009098142A1 (en) * 2008-02-06 2009-08-13 Helm Ag Prasugrel salts with improved properties
EP2107061A1 (en) * 2008-04-02 2009-10-07 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of optically enriched clopidogrel
ES2353853T3 (es) 2008-04-25 2011-03-07 Sandoz Ag SAL HIDROGENOSULFATO DE 2-ACETOXI-5-("ALFA"-CICLOPROPILCARBONIL-2-FLUORBENCIL)-4,5,6,7-TETRAHIDROTIENO[3,2-c]PIRIDINA Y SU PREPARACIÓN.
EP2398468B1 (en) 2009-02-17 2016-11-30 KRKA, D.D., Novo Mesto Pharmaceutical compositions comprising prasugrel base or its pharmaceutically acceptable acid addition salts and processes for their preparation
WO2010132711A1 (en) * 2009-05-13 2010-11-18 Cydex Pharmaceuticals, Inc. Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
DE102009036646A1 (de) 2009-08-07 2011-02-10 Ratiopharm Gmbh Prasugrel in nicht-kristalliner Form und pharmazeutische Zusammensetzung davon
WO2011052499A1 (ja) * 2009-10-28 2011-05-05 第一三共株式会社 貯蔵安定性が改善された医薬組成物
JP2013032289A (ja) * 2009-10-28 2013-02-14 Daiichi Sankyo Co Ltd ワックス安定製剤
WO2011092720A2 (en) * 2010-02-01 2011-08-04 Msn Laboratories Limited Pharmaceutical composition of prasugrel and its pharmaceutically acceptable salts
TR201007926A1 (tr) 2010-07-19 2012-02-21 Sanovel İlaç San.Ve Ti̇c.A.Ş. Prasugrel tablet formülasyonları.
EP2409685A3 (en) 2010-07-19 2012-02-01 Sanovel Ilac Sanayi ve Ticaret A.S. Orally-disintegrating formulations of prasugrel
TR201005900A1 (tr) 2010-07-19 2012-02-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Geliştirilmiş stabiliteye sahip prasugrel granülleri.
TR201006802A1 (tr) * 2010-08-17 2012-03-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Prasugrelin oral yolla dağılan formülasyonları.
CZ2011872A3 (cs) 2011-12-22 2013-07-03 Zentiva, K.S. Farmaceutická formulace prasugrelu hydrobromidu
US8603537B2 (en) 2012-04-02 2013-12-10 Egis Pharmaceuticals Plc Prasugrel containing quickly released stable oral pharmaceutical compositions
WO2014060554A1 (en) 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Prasugrel formulations
WO2014060560A1 (en) 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Solid oral formulations of prasugrel
CN102993210A (zh) * 2012-12-19 2013-03-27 苏春华 一种吡啶并噻吩的新化合物
EP2979693A1 (en) 2014-08-01 2016-02-03 Zaklady Farmaceutyczne Polpharma SA Pharmaceutical composition comprising prasugrel or pharmaceutically acceptable salt thereof and process for its preparation
WO2016122421A1 (en) 2015-01-29 2016-08-04 Pharmactive Ilaç Sanayi Ve Ticaret A.Ş. Stable pharmaceutical compositions containing prasugrel base
EP3158993A1 (en) 2015-10-22 2017-04-26 Zaklady Farmaceutyczne Polpharma SA Process for preparing a tablet comprising prasugrel or pharmaceutically acceptable salt thereof
CN107304216A (zh) * 2016-04-20 2017-10-31 陕西合成药业股份有限公司 噻吩吡啶类衍生物及其制备方法和用途
HU231079B1 (hu) 2016-06-23 2020-06-29 Richter Gedeon Nyrt. Eljárás nagytisztaságú Prasugrel előállítására bromopentil szennyezés eltávolításával
GR1009230B (el) 2016-10-12 2018-02-22 Φαρματεν Αβεε Φαρμακευτικο σκευασμα που περιλαμβανει βεσυλικη πρασουγρελη

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101150B (fi) * 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
JP4001199B2 (ja) * 2000-07-06 2007-10-31 第一三共株式会社 ヒドロピリジン誘導体酸付加塩
HU227746B1 (en) * 2000-07-06 2012-02-28 Ube Industries Hydropyridine derivative acid addition salts, process for their preparation, pharmaceutical compositions containing them and their use
EP1243524A3 (en) * 2001-03-16 2004-04-07 Pfizer Products Inc. Pharmaceutical kit for oxygen-sensitive drugs
JP4394873B2 (ja) * 2001-12-19 2010-01-06 武田薬品工業株式会社 酸素に不安定な化合物を含有する固形組成物およびその安定化方法
SI21302A (sl) * 2002-10-11 2004-04-30 LEK farmacevtska dru�ba d.d. Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
US20050020554A1 (en) * 2003-06-06 2005-01-27 Ahmed Salah U. Stability of hormone formulations
PT1653930E (pt) * 2003-08-05 2008-03-12 Zentiva As Métodos para a estabilização da atorvastatina

Also Published As

Publication number Publication date
KR20100076050A (ko) 2010-07-05
AU2006258102B2 (en) 2011-09-15
WO2006135605A3 (en) 2007-04-12
EP1896019B1 (en) 2009-09-02
EP1896019A2 (en) 2008-03-12
NO20076317L (no) 2008-02-29
HRP20090516T1 (hr) 2009-10-31
NZ564003A (en) 2011-07-29
WO2006135605A2 (en) 2006-12-21
ATE441413T1 (de) 2009-09-15
TWI318571B (en) 2009-12-21
MY151038A (en) 2014-03-31
ES2330373T3 (es) 2009-12-09
DOP2006000126A (es) 2006-12-15
TNSN07466A1 (en) 2009-03-17
ZA200710697B (en) 2009-08-26
US20080176893A1 (en) 2008-07-24
IL187830A0 (en) 2008-04-13
BRPI0611350A2 (pt) 2010-12-07
SI1896019T1 (sl) 2010-01-29
BRPI0611350B1 (pt) 2020-09-15
KR20080008413A (ko) 2008-01-23
CN101193633B (zh) 2011-12-14
RS51194B (sr) 2010-10-31
CA2611668A1 (en) 2006-12-21
EA011693B1 (ru) 2009-04-28
AU2006258102A1 (en) 2006-12-21
EA200702670A1 (ru) 2008-04-28
MA29688B1 (fr) 2008-08-01
PL1896019T3 (pl) 2010-01-29
CN101193633A (zh) 2008-06-04
CY1109502T1 (el) 2014-08-13
ECSP077984A (es) 2008-01-23
DE602006008942D1 (en) 2009-10-15
PT1896019E (pt) 2009-11-19
CA2611668C (en) 2013-10-15
MX2007015431A (es) 2008-02-21
PE20070320A1 (es) 2007-05-12
AR054283A1 (es) 2007-06-13
JP2008543755A (ja) 2008-12-04
BRPI0611350B8 (pt) 2021-05-25
DK1896019T3 (da) 2009-10-26
HK1116422A1 (en) 2008-12-24
TW200718420A (en) 2007-05-16

Similar Documents

Publication Publication Date Title
TNSN07466A1 (en) Formulation of a thienopyridine platelet aggregation inhibitor
WO2009146034A3 (en) Mapk/erk kinase inhibitors and methods of use thereof
MY150542A (en) Cmet inhibitors
JO2985B1 (ar) مثبطات كينازmapk/erk
GEP20125537B (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
IL184303A0 (en) Amino-pyridines as inhibitors of ??-secretase
EP2070935A4 (en) NOVEL COMPOUND, COMPOSITION COMPRISING SAME, AND PROCESS FOR PRODUCING POLYMERIZABLE AMIDE
TNSN08191A1 (en) Kinase inhibitors
SI1761520T1 (sl) Inhibitorji kinaze
GEP20115166B (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
TW200613308A (en) Cyclobutanetetracarboxylate compound and preparation method thereof
WO2005028474A3 (en) Pyrazoloquinoline derivatives as chk-1 inhibitors
WO2010056585A3 (en) Heteroaryl diamide compounds useful as mmp-13 inhibitors
SE0403086D0 (sv) Compounds
IL189286A0 (en) Novel cysteine protease inhibitors and their therapeutic applications
WO2008089005A3 (en) Renin inhibitors
TN2009000130A1 (en) Kinase inhibitors
TW200801011A (en) New compounds II
IL176941A0 (en) New pyridin-2-one compounds useful as inhibitors of thrombin
UA95930C2 (ru) Ингибиторы цистеинпротеаз, фармацевтическая композиция, которая их содержит, и их терапевтическое применение
EP1924275A4 (en) INHIBITORS CONTAINING THIO COMPOUND OF AMINOPEPTIDASE P, THEIR COMPOSITIONS AND METHOD OF USE
EP1896402A4 (en) PROCESS FOR THE SYNTHESIS OF (ALKOXYCARBONYLAMINO) ALKYLSULFONATES
ZA200606245B (en) New pyridin-2-one compounds useful as inhibitors of thrombin
PL376515A1 (pl) Nowe związki α₁-aminoalkano-karbamoiloalkano-fosfinowe użyteczne jako inhibitory aminopeptydazy N oraz sposób ich wytwarzania
HK1118269A (en) Process for the production of (alkoxycarbonylamino)alkyl sulfonates